Limb Girdle Muscular Dystrophy Type 2E Recruitment Study

Limb-Girdle Muscular Dystrophy, Type 2E Clinical Trial

Official title:

Limb Girdle Muscular Dystrophy Type 2E Recruitment Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03492346
• Other study ID #: IRB18-00224
• Status: Recruiting
• Start date: March 28, 2018
• Est. completion date: March 28, 2023

Study information

• Verified date: March 2023
• Source: Nationwide Children's Hospital
• Contact: Sikder Hassan
• Phone: 614-355-2602
• Email: Sikder.Hassan[@]nationwidechildrens.org
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study is to recruit and establish baseline measurements for potential subjects that may be eligible for a gene therapy trial. Specifically, this trial is recruiting individuals who are suspected or have been confirmed to have Limb Girdle Muscular Dystrophy type 2E (LGMD2E).

Description:

This is a longitudinal observational study. It is a 24-month study with the possibility of extending the data time points. Visits will occur monthly. However, at the discretion of the PI, subjects may not be required to return monthly. These subjects may return at intervals ranging from 2 months to a max of 6 months apart.

In the situation that the subjects would fall out of the inclusion criteria or not be eligible for the LGMD2E gene therapy trial, they will be given the opportunity to roll over into the Natural History for LGMD (IRB17-01086). If a subject is invited to screen for the gene therapy trial they will discontinue this trial. By being in this study, it is not a guarantee that subjects will be invited to screen for the LGMD2E gene therapy trial.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: March 28, 2023
• Est. primary completion date: March 28, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years to 15 Years

Eligibility

Inclusion Criteria:

• Age 3-15 inclusive

• Males or females of any ethnic group

• SGCB DNA gene mutations at both alleles or suspected to have LGMD2E based on family and medical history. If suspected, genetic testing will be performed to confirm diagnosis.

• Weakness demonstrated based on history of difficulty running, jumping and climbing stairs

• Ability to complete 100MW timed test within 30-90% predicted

• Perform assessments to the best of their ability with reliable results as deemed by the evaluator.

• Ability to attend scheduled appointments

• Ability to provide informed consent (or assent for ages 9-15)

Exclusion Criteria:

• Confirmed diagnosis of neuromuscular disorder other than LGMD2E

• Has a medical condition or extenuating circumstance that, in the opinion of the investigator, might compromise the subject's ability to comply with the protocol required testing or procedures or compromise the subject's wellbeing, safety, or clinical interpretability

• Subjects with AAVrh74 binding antibody titers > 1:400 as determined by ELISA immunoassay. If endpoint titer is positive at screening, testing may be repeated in 1 month. Antibody testing will be performed on a separate study (IRB17-01101).

• Diagnosis of (or ongoing treatment for) an autoimmune disease

Related Conditions & MeSH terms

• Limb-Girdle Muscular Dystrophy, Type 2E
• Muscular Dystrophies

Locations

Country	Name	City	State
United States	Nationwide Children's Hospital	Columbus	Ohio

Sponsors (2)

Lead Sponsor	Collaborator
Nationwide Children's Hospital	Myonexus Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Baseline Measurements	Establish baseline measurements for potential subjects that may be enrolled into a gene therapy trial.	2 years
Secondary	Disease Progression	Better define the rate of disease progression and skeletal muscle involvement	2 years
Secondary	Registry	Generate a registry of well-characterized LGMD2E patients	2 years